ACC 2016

ACC 2016
The 65th Scientific Session of the American College of Cardiology is the largest meeting of the year for this 52,000 member organization, which represents all cardiovascular professionals. Presentations of clinical trials, professional development sessions, and discussions of treatment guidelines are taking place April 2-4, 2016, at McCormick Place in Chicago, Illinois.
April 05, 2016
The nation's top food and drug regulator enjoyed a warm welcome from colleagues on the final day of the 65th Scientific Session of the American College of Cardiology.
April 05, 2016
While overall data did not suggest a benefit for the drugs, a look at the effects on patients whose cardiac arrests were witnessed shows the benefit of reaching patients quickly.
April 04, 2016
The data were submitted to the FDA following idarucizumabís accelerated approval last year, which is granted to therapies that address an unmet medical need.
April 03, 2016
Results from the GAUSS-3 trial presented Sunday at the American College of Cardiology should be good news for Amgen, but an editorial in JAMA says the cost of evolocumab exceeds "willingness to pay" limits.
April 03, 2016
A small study of sudden out-of-hospital deaths raises questions about the quality of primary care, especially for women.
April 03, 2016
The 2013 guideline update from the American College of Cardiology and the American Heart Association drew criticism when it was presented. Data presented in today's poster session at the ACC Scientific Session revealed unexpected results.
April 03, 2016
The half-day program covered healthy eating, how to prescribe exercise, evidence about stress reduction, and other lifestyle topics, as part of the American College of Cardiology's focus on prevention.
April 02, 2016
Greetings from First Lady Michelle Obama and a lecture from a non-cardiologist on population health set the stage for the 65th Scientific Session of the American College of Cardiology. Prevention is the focus of this year's meeting.
April 02, 2016
Results from the HOPE-3 trial, presented on the opening day of the 65th Scientific Session of the American College of Cardiology, suggest cholesterol-lowering statins could have preventive benefits in broader groups of patients than previously thought.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!